ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014
Abnormalities in white matter microstructure associated with chronic ketamine use.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Brain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review.Frontiers in neuroanatomy · 2022Pooled it
- Ketamine metabolite pilot study in a suicidal depression trial.Journal of psychiatric research · 2019Trial
- Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Suspected cumulative neuro-ophthalmic toxicity after chronic oral exposure to the veterinary anesthetic tiletamine: a case report.Frontiers in veterinary science · 2026Article
- Molecular Mechanisms Underlying Chronic High-Dose Ketamine-Induced Apoptosis in the Hippocampus: A Narrative Review.Neurochemical research · 2025Review
- Potential molecular pathways and therapeutic implications of rapid-acting antidepressants on myelin biology: a scoping review.Frontiers in neuroscience · 2025Review
- Neurotoxicity mechanisms and clinical implications of six common recreational drugs.Frontiers in pharmacology · 2025Review
- Adolescent substance use initiation and long-term neurobiological outcomes: insights, challenges and opportunities.Molecular psychiatry · 2024Review
- Aberrant sense of agency induced by delayed prediction signals in schizophrenia: a computational modeling study.Schizophrenia (Heidelberg, Germany) · 2023Article
- Ketamine plus Alcohol: What We Know and What We Can Expect about This.International journal of molecular sciences · 2022Review
- Ketamine use disorder: preclinical, clinical, and neuroimaging evidence to support proposed mechanisms of actions.Intelligent medicine · 2022Article
- White matter alterations in chronic MDMA use: Evidence from diffusion tensor imaging and neurofilament light chain blood levels.NeuroImage. Clinical · 2022Article
- Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling.Molecular psychiatry · 2021Article
- Effects of early ketamine exposure on cerebral gray matter volume and functional connectivity.Scientific reports · 2020Article
- Cue-Induced Brain Activation in Chronic Ketamine-Dependent Subjects, Cigarette Smokers, and Healthy Controls: A Task Functional Magnetic Resonance Imaging Study.Frontiers in psychiatry · 2018Article
- Article
- Cognitive dysfunction in major depression and Alzheimer's disease is associated with hippocampal-prefrontal cortex dysconnectivity.Neuropsychiatric disease and treatment · 2017Review
- Chronic Ketamine Exposure Causes White Matter Microstructural Abnormalities in Adolescent Cynomolgus Monkeys.Frontiers in neuroscience · 2017Article
- Disrupted salience network functional connectivity and white-matter microstructure in persons at risk for psychosis: findings from the LYRIKS study.Psychological medicine · 2016Article
- Practical application of the neuroregenerative properties of ketamine: real world treatment experience.Neural regeneration research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that has been found to induce schizophrenia-type symptoms in humans and is a potent and fast-acting antidepressant. It is also a relatively widespread drug of abuse, particularly in China and the UK. Acute administration has been well characterized, but the effect of extended periods of ketamine use-on brain structure in humans-remains poorly understood. We measured indices of white matter microstructural integrity and connectivity in the brain of 16 ketamine users and 16 poly-drug-using controls, and we used probabilistic tractography to quantify changes in corticosubcortical connectivity associated with ketamine use. We found a reduction in the axial diffusivity profile of white matter in a right hemisphere network of white matter regions in ketamine users compared with controls. Within the ketamine-user group, we found a significant positive association between the connectivity profile between the caudate nucleus and the lateral prefrontal cortex and dissociative experiences. These findings suggest that chronic ketamine use may be associated with widespread disruption of white matter integrity, and white matter pathways between subcortical and prefrontal cortical areas may in part predict individual differences in dissociative experiences due to ketamine use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.